Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC30 in Obesity
NCT06679959Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASC30 in obesity (11 cohorts), sponsored by Ascletis Pharma Inc. Primary endpoint: Incidence of Adverse Events and Serious Adverse Events. Started Sep 2024; status: completed.
02
Drugs
ASC30
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06679959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679959.